In the last trading session, 3.92 million ATAI Life Sciences N.V (NASDAQ:ATAI) shares changed hands as the company’s beta touched 1.18. With the company’s per share price at $1.82 changed hands at -$0.17 or -8.54% during last session, the market valuation stood at $353.07M. ATAI’s last price was a discount, traded about -56.59% off its 52-week high of $2.85. The share price had its 52-week low at $1.03, which suggests the last value was 43.41% up since then.
Analysts gave the ATAI Life Sciences N.V (ATAI) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ATAI as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. ATAI Life Sciences N.V’s EPS for the current quarter is expected to be -0.15.
ATAI Life Sciences N.V (NASDAQ:ATAI) trade information
Instantly ATAI was in red as seen at the end of in last trading. With action -20.87%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 36.84%, with the 5-day performance at -20.87% in the red. However, in the 30-day time frame, ATAI Life Sciences N.V (NASDAQ:ATAI) is 20.53% up.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 69.67% from its current market value. According to analyst projections, ATAI’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -229.67% plunge from its current level, while the stock would need to soar -229.67% for it to hit the projected low.
ATAI Life Sciences N.V (ATAI) estimates and forecasts
Year-over-year growth is forecast to reach 159.03% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 250k. The company’s revenue for the corresponding quarters a year ago was 18k. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 1,288.89%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 44.19%. The 2025 estimates are for ATAI Life Sciences N.V earnings to decrease by -216.57%.
ATAI Dividends
ATAI Life Sciences N.V is expected to release its next quarterly earnings report in March.
MORGAN STANLEY holds the second largest percentage of outstanding shares, with 1.7111% or 2.72 million shares worth $3.62 million as of 2024-06-30.
Among Mutual Funds, the top two as of Nov 30, 2024 were iShares Biotechnology ETF and Morgan Stanley Inst Fund Inc-Inception Port . With 771.79 shares estimated at $1.4 million under it, the former controlled 0.46% of total outstanding shares. On the other hand, Morgan Stanley Inst Fund Inc-Inception Port held about 0.31% of the shares, roughly 511.99 shares worth around $0.93 million.
